April 29, 2025
Authored and Edited by Christopher B. Anderson; Erik R. Puknys; Prince Ene*
In Maquet Cardiovascular LLC v. Abiomed Inc., No. 2023-2045 (Fed. Cir. Mar. 21, 2025), the Federal Circuit vacated a judgment of non-infringement regarding Maquet’s U.S. Patent No. 10,238,783, ruling that the district court improperly narrowed the claim scope by misapplying prosecution disclaimer.
Marquet asserted that Abiomed infringed certain claims of the ’783 patent directed to a system for deploying a blood pump to a desired location in a patient’s circulatory system. At issue on appeal were the district court’s claim construction rulings related to three terms in the ’783 patent. The district court accepted Abiomed’s arguments that prosecution history from prior applications required reading negative limitations into the claims—namely, that the claimed “guide mechanism comprising a lumen” does not encompass a lumen that is distal to a cannula or that passes through the pump’s rotor blades.
The Federal Circuit disagreed, finding the district court overextended the doctrine of prosecution disclaimer. First, the Court held that the claims in the ’783 patent were not sufficiently similar to those in its parent patent to justify importing limitations from its prosecution. Second, although the ’783 patent and another prior application shared nearly identical “guide wire” language, Maquet had not clearly disavowed claim scope during the earlier prosecution. The Court reasoned that Maquet’s silence or vague statements during PTO proceedings and IPRs did not amount to the “clear and unmistakable” disavowal required.
Because the judgment was based entirely on these constructions, the court vacated and remanded for further proceedings.
*Prince Ene is a Law Clerk at Finnegan.
Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Federal Circuit IP Blog
When “and” and “e.g.” Matter: Federal Circuit Revives VLSI vs. Intel Case
May 14, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.